Sunshine Biopharma (SBFM) EBITDA (2011 - 2026)

Sunshine Biopharma has reported EBITDA for 15 years, with the latest figure at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 31.93% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$5.6 million (up 6.8% YoY), and the FY2025 full-year result was -$5.2 million, up 21.76% from the prior year.
• EBITDA for Q1 2026 stood at -$1.5 million, up from -$1.9 million in the prior quarter.
• The five-year high for EBITDA was -$346163.0 in Q3 2024, with the low at -$23.3 million in Q4 2022.
• Historically, EBITDA has averaged -$2.6 million across 5 years, with a median of -$1.3 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA sank 3618.1% — and 2023, when it surged 96.74%.
• Sunshine Biopharma's EBITDA stood at -$23.3 million in 2022, then surged by 96.74% to -$758468.0 in 2023, then slumped by 316.2% to -$3.2 million in 2024, then soared by 40.27% to -$1.9 million in 2025, then climbed by 19.28% to -$1.5 million in 2026.
• The last three EBITDA figures came in at -$1.5 million (Q1 2026), -$1.9 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.